Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma
- PMID: 2783325
Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma
Abstract
One of the difficulties encountered with the treatment of human B cell malignancies with anti-Id antibodies is the emergence of Id variants. The current study was designed to investigate this phenomenon further by using the murine B cell lymphoma model 38C13. Tumors were harvested that developed despite treatment with the anti-Id antibody S1C5 in mice inoculated with 38C13 cells and evaluated by immunofluorescence. Various phenotypes were found among escaping tumor cells. Some cells continued to react with S1C5 whereas others lost S1C5 reactivity. Among these latter cells, some continued to express surface IgM kappa, whereas others no longer expressed surface mu or kappa. After Id variant cell lines were established, immunofluorescence and ELISA of cell lysates from the surface IgM kappa- lines revealed persistent intracellular mu H chain but no detectable kappa. Surface IgM kappa+ lines were fused with myeloma cells and the Ig proteins secreted by the resultant hybridomas analyzed. The apparent m.w. of the mu-chains of these rescued Ig was the same as wild-type 38C13, whereas the kappa-chains were either the same or different in m.w. from the wild type. The IgM kappa of the variant line, T3C, weakly reacted with S1C5 and did not react with other anti-Id antibodies. The IgM kappa of the other variants were nonreactive with all the antibodies. Immunofluorescence of these surface Ig+ variants confirmed this finding. Some of the surface Ig+ and Ig- variant lines grew identically to wild-type tumor in vivo, but only the weakly S1C5-reactive variant T3C was inhibited in its growth by S1C5. Moreover, T3C was the only one of these lines capable of being lysed in vitro with S1C5 by antibody-dependent cellular cytotoxicity. Further studies revealed that surface Ig+ and Ig- variants emerge in escaping tumors with similar frequency and that these variants represent a major mode of tumor escape from anti-Id treatment in this model.
Similar articles
-
Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.J Immunol. 1990 Mar 15;144(6):2436-45. J Immunol. 1990. PMID: 1690244
-
Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants.J Immunol. 1988 Jul 1;141(1):333-9. J Immunol. 1988. PMID: 3132505
-
Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.J Immunol. 1991 Dec 1;147(11):4035-44. J Immunol. 1991. PMID: 1834746
-
Syngeneic antiidiotypic immune responses to a B cell lymphoma. Comparison between heavy chain hypervariable region peptides and intact Ig as immunogens.J Exp Med. 1985 Jul 1;162(1):19-34. doi: 10.1084/jem.162.1.19. J Exp Med. 1985. PMID: 3925067 Free PMC article. Review.
-
Therapy of lymphoma directed at idiotypes.J Natl Cancer Inst Monogr. 1990;(10):61-8. J Natl Cancer Inst Monogr. 1990. PMID: 1693283 Review.
Cited by
-
Specificity and biologic activities of novel anti-membrane IgM antibodies.Oncotarget. 2016 Nov 15;7(46):74701-74723. doi: 10.18632/oncotarget.12506. Oncotarget. 2016. PMID: 27732950 Free PMC article.
-
Immunotherapy of B lymphoma by anti-idiotype antibodies: characterization of variant tumour cells appearing a long time after the initial tumour inoculation.Cancer Immunol Immunother. 1991;34(1):43-8. doi: 10.1007/BF01741323. Cancer Immunol Immunother. 1991. PMID: 1760810 Free PMC article.
-
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7. doi: 10.1073/pnas.94.20.10833. Proc Natl Acad Sci U S A. 1997. PMID: 9380720 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Research Materials